39P - Impact of GSTP1 and ABCC4 genes polymorphism on outbreak of cyclophosphamide-based chemotherapy-induced grade 3/4 febrile neutropenia in Iranian br...

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Cytotoxic agents
Complications/Toxicities of treatment
Translational Research
Presenter Maryam Mobaraki
Citation Annals of Oncology (2016) 27 (suppl_9): ix9-ix18. 10.1093/annonc/mdw574
Authors M. Mobaraki1, H. Dehghan Manshadi2, A. Faraji1, M. Zare2, Z. Siavashpour3, M.H. Sanati1
  • 1Medical Genetics, National Institute of Genetic Engineering and Biotechnology (NIGEB), 14965161 - Tehran/IR
  • 2Clinical Oncology, Shohadaye 7 Tir, 10000 - Tehran/IR
  • 3Medical Radiation Engineering, Shahid Beheshti University of Medical Sciences, 11111 - Tehran/IR

Abstract

Background

Breast cancer is the most common cancer among women. Cyclophosphamide-based chemotherapy is an effective treatment procedure for breast cancer but some toxicities such as neutropenia are seen to emerge during chemotherapy. GSTP1 and ABCC4 are two significant enzymes that are involved in cyclophosphamide metabolism and transport respectively.

Methods

In this study, we investigated the impact of two common polymorphisms of GSTP1 (rs1695) and ABCC4 (rs9561778) genes on outbreak of grade 3/4 febrile neutropenia in Iranian breast cancer patients using ARMS-PCR and sequencing methods. Results analysis was done with SPSS Software.

Results

Based on statistical analysis, no meaningful association between the above-mentioned polymorphisms and outbreak of grade 3/4 febrile neutropenia was observed. But higher frequency of allele A of GSTP1 (rs9561778) and allele G of ABCC4 (rs1695) genes polymorphism in the control group indicate their protective role against outbreak of grade 3/4 febrile neutropenia. Although clinical findings demonstrated statistically meaningful association of cancer stage IIIC (p = 0.037) and existence of other diseases (p = 0.026) in addition to breast cancer with outbreak of grade 3/4 febrile neutropenia.

Conclusions

Based on our results, combination of molecular and clinical findings could be useful in prediction of high risk breast cancer patients for outbreak of grade 3/4 febrile neutropenia.

Clinical trial indentification

Legal entity responsible for the study

Medical Genetics Department of National Institute of Genetic Engineering and Biotechnology, Radiation Oncology Department of shohadaye 7Tir hospital of Iran University of Medical Sciences

Funding

Medical Genetics Department of National Institute of Genetic Engineering and Biotechnology, Radiation Oncology Department of shohadaye 7Tir hospital of Iran University of Medical Sciences

Disclosure

All authors have declared no conflicts of interest.